Results at 2 years of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with DMD

被引：1
|
作者：
Mendell, J. R. [1 ]
Rodino-Klapac, L. [1 ]
Sahenk, Z. [1 ]
Roush, K. [1 ]
Bird, L. [1 ]
Lowes, L. P. [1 ]
Alfano, L. [1 ]
Gomez, A. M. [1 ]
Lewis, S. [1 ]
Malik, V. [1 ]
Shontz, K. [1 ]
Flanigan, K. M. [1 ]
Kean, J. R. [1 ]
Allen, H. D. [1 ]
Shilling, C. [1 ]
Sazani, P. [2 ]
Saoud, J. [2 ]
Kaye, E. M. [2 ]
机构：
[1] Nationwide Childrens Hosp, Columbus, OH USA
[2] Sarepta Therapeut, Cambridge, MA USA
来源：
NEUROMUSCULAR DISORDERS | 2013年 / 23卷 / 9-10期
关键词：
D O I：
10.1016/j.nmd.2013.06.581
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：804 / 805
页数：2
相关论文
共 50 条
  • [1] A Phase IIb Placebo-Controlled Study of the Exon-Skipping Drug Eteplirsen in Subjects with Duchenne Muscular Dystrophy
    Mendell, Jerry
    Rodino-Klapac, Louise
    Sahenk, Zarife
    Roush, Kandice
    Bird, Lauren
    Lowes, Linda
    Alfano, Lindsay
    Gomez, Ana Maria
    Lewis, Sarah
    Shontz, Kim
    Flanigan, Kevin
    Taylor, Laura
    Walker, Christopher
    Campbell, Katie
    Allen, Hugh
    Schilling, Christopher
    Kean, John
    Sazani, Peter
    Kaye, Edward
    NEUROLOGY, 2012, 79 (11) : E87 - E88
  • [2] Pulmonary Function is Stable in Patients with Duchenne Muscular Dystrophy (DMD) Treated with Exon-Skipping Drug Eteplirsen in Phase 2b Study
    Mendell, J. R.
    Lowes, L. P.
    Alfano, L.
    Duda, P.
    Saoud, J.
    Kaye, E. M.
    ANNALS OF NEUROLOGY, 2014, 76 : S237 - S237
  • [3] Pulmonary function is stable through week 120 in patients with Duchenne muscular dystrophy (DMD) treated with exon-skipping drug eteplirsen in phase 2b study
    Mendell, J. R.
    Lowes, L. P.
    Alfano, L.
    Saoud, J.
    Duda, P.
    Kaye, E.
    NEUROMUSCULAR DISORDERS, 2014, 24 (9-10) : 828 - 829
  • [4] Safety and tolerability of Eteplirsen in patients 6-48 Months old with DMD amenable to exon 51 skipping: an open-label extension study
    Mercuri, E.
    Seferian, A.
    Deconinck, N.
    Orogun, L.
    Ni, X.
    Zhang, W.
    Drummond, K.
    Sehinovych, I.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S103 - S103
  • [5] Upgrading U7snRNA To Complete Efficient Rescue of Dystrophin by Exon-Skipping in DMD Patients
    Goyenvalle, Aurelie
    Babbs, Arran
    Garcia, Luis
    Davies, Kay E.
    MOLECULAR THERAPY, 2009, 17 : S152 - S152
  • [6] Clinical safety of eteplirsen, a phosphorodiamidate morpholino oligomer (PMO), in Duchenne muscular dystrophy (DMD) patients amenable to skipping exon 51 of the DMD gene
    Mendell, J.
    Powers, J.
    Duda, P.
    Eliopoulos, H.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S153 - S154
  • [7] Phase 2 multiple ascending-dose study of SRP-5051 PPMO in patients with DMD amenable to exon 51 skipping: Part A results
    Campbell, Craig
    Mathews, Katherine
    van de Rijn, Marc
    Palatinsky, Emanuel
    Ni, Xiao
    Sha, Nanshi
    Sehinovych, Ihor
    Tinsley, Jon
    Malhotra, Jyoti
    O'Rourke, Erin
    Phan, Han
    GENETICS IN MEDICINE, 2022, 24 (03) : S133 - S133
  • [8] Results of the Eteplirsen Phase 2b and Phase 2b Extension Study in Duchenne Muscular Dystrophy
    Kaye, Ed
    NUCLEIC ACID THERAPEUTICS, 2012, 22 (06) : A13 - A13
  • [9] A phase 1/2 study of DYNE-251 in males with DMD mutations amenable to exon 51 skipping: DELIVER study design
    Naylor, M.
    Mix, C.
    Han, B.
    Dugar, A.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S69 - S70
  • [10] A Novel Clinical Trial Design to Evaluate the Efficacy and Safety of Two Exon-Skipping PMOs, SRP-4045 and SRP-4053, in Patients with Duchenne Muscular Dystrophy (DMD)
    Kaye, E. M.
    Laforet, G. L.
    Saoud, J.
    ANNALS OF NEUROLOGY, 2015, 78 : S219 - S220
12345